BSV breaks ground for ₹200 crore biopharma plant at Genome Valley

Biotech firm Bharat Serums and Vaccines (BSV) broke ground for a ₹200 crore biopharmaceutical manufacturing plant at Genome Valley in Hyderabad on Thursday.

The facility, to come up on 10 acres, will produce women’s health products, rabies vaccines, immunoglobulins and hormones. It will cater to domestic and export markets, BSV said in a release.

With the facility, BSV aims to increase its capacity to produce injectables with the commissioning of the fillfinish formulation line in phase 1 and an additional multiproduct line in phase 2 of the project. In a release, the company said it aims to provide longterm employment opportunities to the people of Telangana as well as upskilling of capabilities.

BSV has a manufacturing plant in Ambernath, Maharashtra, which caters to domestic and more than 80 export markets and a manufacturing facility in Aachen, Germany, which serves the international markets.

K.T. Rama Rao with BSV MD and CEO Sanjiv Navangul at the ground-breaking of the company’s facility on Thursday.

Industries and IT Minister K.T Rama Rao, who participated in the groundbreaking programme on Thursday, said that BSV’s decision to host the facility here reflects the huge opportunity, potential and comprehensive ecosystem that Genome Valley offers to the Life Sciences sector.

Genome Valley is home to more than 200 companies with a scientific workforce of about 25,000 professionals, the company said.

“We are delighted to be a part of the Genome Valley ecosystem that promotes research and innovation and provides a conducive scientific temper for biopharma companies to operate,” BSV Managing Director and CEO Sanjiv Navangul said.